MS patients exhibit decreased PPARγ expression in peripheral blood mononuclear cells (PMNC) compared with controls (Klotz et al., 2005) and in obese MS patients, pioglitazone (a PPARγ agonist) decreases inflammatory activity and the development of new brain lesions (Negrotto et al., 2016). This evidence concerns the gene PPARG and myeloid sarcoma.